FDA’s accelerated approval program: Is change on the way?
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy